VivaVision Biotech Receives FDA Approval for Streamlined VVN461HD Development Path in Non-Infectious Anterior Uveitis
Key Insights
VivaVision Biotech (search) received positive FDA feedback confirming their ongoing Phase III study in China can serve as one of two pivotal trials required for VVN461HD (search)'s New Drug Application.
The FDA acknowledged positive Phase II results for VVN461HD (search) in treating non-infectious anterior uveitis and agreed on Phase III study design parameters.
The company now only needs to conduct a single Phase III pivotal trial in the United States, significantly reducing development timeline and R&D investment.
VivaVision Biotech (search), a late clinical-stage biopharmaceutical company focused on innovative ophthalmic drugs, announced it has received positive written feedback from the U.S. Food and Drug Administration (FDA) regarding VVN461HD (search) for the treatment of non-infectious anterior uveitis (NIAU). The FDA's meeting minutes confirm that the company's ongoing Phase III clinical study in China can serve as one of the two pivotal trials required to support a future New Drug Application (NDA) for this indication.
FDA Recognition of Chinese Clinical Data
The positive feedback follows VivaVision's Type C meeting application and subsequent video conference with the FDA to discuss VVN461HD (search) development. The FDA positively acknowledged the results of the Phase II clinical trial of VVN461HD for non-infectious anterior uveitis completed by VivaVision in China and reached agreement with the company on the design of the next Phase III clinical studies.
Crucially, the FDA agreed to recognize the Phase III clinical trial conducted in China as one of the two pivotal trials required for the subsequent NDA. This regulatory alignment significantly streamlines the development pathway for VVN461HD (search).
Accelerated Development Timeline
Based on this feedback, VivaVision only needs to conduct one pivotal Phase III clinical trial in the United States before submitting the NDA, which will significantly shorten the development timeline and reduce R&D investment for this product. The company expects to initiate the Phase III clinical trial in the United States in the first half of 2026.
"Since the initiation of clinical trials for VVN461HD (search) in 2023, it has demonstrated rapid clinical progress and excellent efficacy, reflecting the clinical development and execution capabilities of the VivaVision team," said Dr. Albert Tsai, Chief Medical Officer at VivaVision Biotech (search). "We are very grateful for the FDA's recognition of the Phase II clinical trial of VVN461HD conducted in China, which signifies a significant reduction in the pre-market development timeline for this product."
About VVN461HD and Company Pipeline
VVN461HD (search) is a dual JAK1 (search)/TYK2 (search) inhibitor specifically developed for the treatment of non-infectious anterior uveitis, with "HD" denoting "high-dose" formulation. The drug is part of VivaVision's broader pipeline of ophthalmic therapies, which includes VVN461LD (search) (a low-dose dual JAK1/TYK2 inhibitor for post-operative inflammation), VVN001 for dry eye syndrome, VVN1901 for neurotrophic keratitis, and VVN481 for posterior/pan-uveitis treatment.
Founded in 2016, VivaVision Biotech (search) is dedicated to advancing first/best-in-class therapies for ocular diseases and continues to discover and develop additional treatments for anterior and posterior segment eye diseases to address unmet patient needs.